These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24406081)

  • 1. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder.
    Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH
    Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study.
    Ruhé HG; Booij J; Veltman DJ; Michel MC; Schene AH
    J Clin Psychiatry; 2012 Apr; 73(4):451-9. PubMed ID: 21903032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
    Kugaya A; Sanacora G; Staley JK; Malison RT; Bozkurt A; Khan S; Anand A; Van Dyck CH; Baldwin RM; Seibyl JP; Charney D; Innis RB
    Biol Psychiatry; 2004 Oct; 56(7):497-502. PubMed ID: 15450785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
    Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
    Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.
    Catafau AM; Perez V; Plaza P; Pascual JC; Bullich S; Suarez M; Penengo MM; Corripio I; Puigdemont D; Danus M; Perich J; Alvarez E
    Psychopharmacology (Berl); 2006 Dec; 189(2):145-53. PubMed ID: 17033844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder.
    Simoons M; Mulder H; Appeldoorn JTY; Risselada AJ; Schene AH; van Schaik RHN; van Roon EN; Ruhé EG
    Psychiatr Genet; 2020 Feb; 30(1):19-29. PubMed ID: 31634334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652.
    Kent JM; Coplan JD; Lombardo I; Hwang DR; Huang Y; Mawlawi O; Van Heertum RL; Slifstein M; Abi-Dargham A; Gorman JM; Laruelle M
    Psychopharmacology (Berl); 2002 Dec; 164(4):341-8. PubMed ID: 12457263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines].
    Ruhé HG; Booij J; van Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene A
    Tijdschr Psychiatr; 2010; 52(9):615-25. PubMed ID: 20862644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in serotonin transporter binding affinity in patients with major depressive disorder and night eating syndrome.
    Lundgren JD; Amsterdam J; Newberg A; Allison KC; Wintering N; Stunkard AJ
    Eat Weight Disord; 2009 Mar; 14(1):45-50. PubMed ID: 19367140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM.
    Herold N; Uebelhack K; Franke L; Amthauer H; Luedemann L; Bruhn H; Felix R; Uebelhack R; Plotkin M
    J Neural Transm (Vienna); 2006 May; 113(5):659-70. PubMed ID: 16465456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
    Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
    J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study.
    Shang Y; Gibbs MA; Marek GJ; Stiger T; Burstein AH; Marek K; Seibyl JP; Rogers JF
    J Clin Psychopharmacol; 2007 Feb; 27(1):71-5. PubMed ID: 17224717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas.
    Lanzenberger R; Kranz GS; Haeusler D; Akimova E; Savli M; Hahn A; Mitterhauser M; Spindelegger C; Philippe C; Fink M; Wadsak W; Karanikas G; Kasper S
    Neuroimage; 2012 Nov; 63(2):874-81. PubMed ID: 22828162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.
    Stengler-Wenzke K; Müller U; Barthel H; Angermeyer MC; Sabri O; Hesse S
    Neuropsychobiology; 2006; 53(1):40-5. PubMed ID: 16397403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
    Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
    Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
    Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
    Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder.
    Victor TA; Furey ML; Fromm SJ; Ohman A; Drevets WC
    Arch Gen Psychiatry; 2010 Nov; 67(11):1128-38. PubMed ID: 21041614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging.
    Joensuu M; Tolmunen T; Saarinen PI; Tiihonen J; Kuikka J; Ahola P; Vanninen R; Lehtonen J
    Psychiatry Res; 2007 Feb; 154(2):125-31. PubMed ID: 17289353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.